Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cemacabtagene ansegedleucel by Allogene Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
Cemacabtagene ansegedleucel by Allogene Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....
Cemacabtagene ansegedleucel by Allogene Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
ALLO-501 by Allogene Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
ALLO-501 is under clinical development by Allogene Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
ALLO-501A by Allogene Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ALLO-501A is under clinical development by Allogene Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
ALLO-501A by Allogene Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
ALLO-501A is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...